Novavax | NVAX - Loan Capital


Novavax reported $246.3M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Adma Biologics USD 193.58M 124.25M Mar/2026
Agenus USD 169.66M 146.06M Dec/2025
AstraZeneca USD 25.96B 177M Mar/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Cassava Sciences USD 0 0 Dec/2024
Geron USD 119.83M 286K Mar/2026
GlaxoSmithKline GBP 14.01B 696M Mar/2026
MannKind USD 548.07M 371K Mar/2026
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 603M 7M Mar/2026
Novartis USD 37.45B 7.86B Mar/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.57B 1.08B Mar/2026
Sanofi EUR 13.84B 1.88B Mar/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
TG Therapeutics USD 745.14M 499.5M Mar/2026